ECOG-ACRIN Fall 2013 Meeting
Genitourinary Early Modality Session
Meeting Agenda
Nov. 15, 2013; 11:30 AM - 1:00 PM
Hollywood, FL

A. Introductions and welcome

B. ECOG-ACRIN Trials Under Development Needing Input:
   1) E4813: An International Rare Cancers Initiative Study in Penis Cancer (InPACT)
      ➢ Multidisciplinary approach, but these patients start with urologists

   2) ECOG-ACRIN E3813: A Phase II/III Study of Anti-1-amino-3-fluorine 18-fluorocyclobutane-1-carboxylic acid (FACBC) PET/CT for Improved Cancer Detection in Men With Persistent or Recurrent Disease After Curative-Intent Radical Prostatectomy
      ➢ Coming from ACRIN side of novel PSMA Pet imaging agent
      ➢ Looking for men with biochemical recurrence and wanting to get tissue from those that light up

   3) E2813: A Phase III Trial In Men with high-risk Prostate Cancer of Adjuvant Androgen Deprivation with or without Enzalutamide (IMPROVE)
      ➢ Buy-in from Urology: is there a need, who are the highest risk individuals that can be easily identified- will urologists be interested

   4) E1812: A randomized phase III study comparing perioperative BMS-936558 vs. placebo in unfavorable localized renal cell carcinoma
      ➢ Need to identify patients early and have them participate in a trial

C. New Concept/Trial Ideas:
   1) Active Surveillance
      ➢ Tissue diagnostics (Genomic Health, Oncotype Dx, Myriad, etc)
      ➢ Advanced imaging (MRI Fusion)
      ➢ Extended template biopsy

   2) Neoadjuvant RP trial
      ➢ Possibly with enzalutamide
      ➢ Possibly randomized trial of surgery vs RT for high risk CaP

   3) Check Point inhibitors (PD-1 and ipilimumab) and RT failures
      ➢ Salvage cryotherapy with check point inhibitors